Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | MME | P08473 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870250 | 1.00 | FOLH1 (0.51) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL8249827 | 0.89 | MME (0.62) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5869511 | 0.86 | KDM4E (0.47) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5870373 | 0.86 | KDM4E (0.47) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5869314 | 0.85 | MME (0.53) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL8255762 | 0.85 | MME (0.53) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5870306 | 0.84 | NR4A2 (0.53) | MMEACECPA1ACE2GPR132 | |
| SCHEMBL5870305 | 0.84 | NR4A2 (0.53) | MMEACECPA1ACE2GPR132 | |
| SCHEMBL5869745 | 0.84 | MME (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5869757 | 0.84 | GPR132 (0.60) | FOLH1MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | FOLH1 229/4885MME 11/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.